The criticality of high-resolution N-linked carbohydrate assays and detailed characterization of antibody effector function in the context of biosimilar development

References

• Kozlowski S, Woodcock J, Midthun K, Sherman RB. Developing the nation's biosimilars program. N Engl J Med 2011; 365:385-8; PMID:21812668; http://dx.doi.org/10.1056/NEJMp1107285
   PubMed Web of Science ®Google Scholar
• Kálmán-Szekeres Z, Olajos M, Ganzler K. Analytical aspects of biosimilarity issues of protein drugs. J Pharm Biomed Anal 2012; 69:185-95; http://dx.doi.org/10.1016/j.jpba.2012.04.037
   PubMed Web of Science ®Google Scholar
• Carter P, Presta L, Gorman CM, Ridgway JBB, Henner D, Wong WLT, Rowland AM, Kott C, Carver ME, Spepard HM. Humanization of an anti-p185Her2 antibody for human cancer therapy. Proc Natl Acad Sci U S A 1992; 89:4285-9; http://dx.doi.org/10.1073/pnas.89.10.4285
   PubMed Web of Science ®Google Scholar
• Knight DM, Trinh H, Le J, Siegel S, Shealy D, McDonough M, Scallon B, Moore MA, Vilcek J, Daddona P, et al. Construction and intial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol 1993; 30:1443-53; PMID:8232330; http://dx.doi.org/10.1016/0161-5890(93)90106-L
   PubMed Web of Science ®Google Scholar
• Jian X-R, Song A, Bergelson S, Arroll T, Parehk B, May K, Chung S, Strouse R, Mire-Sluis A, Schenerman M. Advances in the assessment and aontrol of the effector functions of therapeutic antibodes. Nat Rev 2011; 10:101-10; PMID:21283105
   PubMedGoogle Scholar
• Mitoma H, Horiuchi T, Tsukamoto H, Tamimoto Y, Kimoto Y, Uchino A, To K, Harashima S-i, Hatta N, Harada M. Mechanisms of cytoxic effect of anti-tumor necrosis factor agens on transmembrane tumor necrosis factor alpha-expressing cells. Arthiritis Rheumatism 2008; 58:1248-57; http://dx.doi.org/10.1002/art.23447
   PubMed Web of Science ®Google Scholar
• Hudis C. Trastuzumab – mechamism of action and use in clinical practice. N Engl J Med 2007; 357:39-51; PMID:17611206; http://dx.doi.org/10.1056/NEJMra043186
   PubMed Web of Science ®Google Scholar
• Harris RJ, Kabakoff B, Macchi FD, Shen FJ, Kwong M, Andya JD, Shire SJ, Bjork N, Totpal K, Chen AB. Identification of multiple sources of charge heterogeneity in a recombinant antibody. J Chromatography B 2001; 752:233-45; http://dx.doi.org/10.1016/S0378-4347(00)00548-X
   PubMed Web of Science ®Google Scholar
• Hacker DL, De Jesus M, Wurm FM. 25 years of recombinant proteins from reactor-grown cells — Where do we go from here? Biotechnol Adv 2009; 27:1023-7; PMID:19463938; http://dx.doi.org/10.1016/j.biotechadv.2009.05.008
   PubMed Web of Science ®Google Scholar
• De Jesus M, Wurm FM. Manufacturing recombinant proteins in kg-ton quantities using animal cells in bioreactors. Eur J Pharm and Biopharm 2011; 78:184-8; PMID:21256214; http://dx.doi.org/10.1016/j.ejpb.2011.01.005
   PubMed Web of Science ®Google Scholar
• Lazar G, Dang W, Karki S, Vafa O, Peng J, Hyun L, Chan C, Chung H, Elvazi A, Yoder S, et al. Engineered antibody Fc variants with enhanced effector function. Proc Natl Acad Sci 2006; 103:4005-10; http://dx.doi.org/10.1073/pnas.0508123103
   PubMed Web of Science ®Google Scholar
• Moore G, Chen H, Karki S, Lazar G. Engineered Fc variant antibodies with enhanced ability to recruite complement and mediate effector funtions. mAbs 2010; 2:181-9; PMID:20150767; http://dx.doi.org/10.4161/mabs.2.2.11158
   PubMed Web of Science ®Google Scholar
• Saphire EO, Stanfield R, Crispin MDM, Parren P, Rudd P, Dwek R, Burton D, Wilson I. Contrasting IgG structures reveal extreme asymmetry and flexibility. J Mol Biol 2002; 319:9-18; PMID:12051932; http://dx.doi.org/10.1016/S0022-2836(02)00244-9
   PubMed Web of Science ®Google Scholar
• Kanda Y, Yamada T, Mori K, Okazaki A, Inoue M, Kitajima-Miyama K, Kuni-Kamochi R, Nakano R, Yano K, Kakita S, et al. Comparison of biological activity among nonfucosylated therapeutic IgG1antibodies with three different N-linked Fc oligosaccharides: the high-mannose,hybrid, and complex types. Glycobiology 2006; 17:104-18; PMID:17012310; http://dx.doi.org/10.1093/glycob/cwl057
   PubMed Web of Science ®Google Scholar
• Niwa R, Natsume A, Uehara A, Wakitani M, Iida S, Uchida K, Satoh M, Shitara K. IgG subclass-independent improvement of antibody-dependent cellular cytotoxicity by fucose removal from Asn297-linked oligosaccharides. J Immunol Methods 2006; 306:151-60; http://dx.doi.org/10.1016/j.jim.2005.08.009
   Web of Science ®Google Scholar
• Yu M, Brown D, Reed C, Chung S, Lutman J, Stefanich E, Wong A, Stefan J-P, Bayer R. Production, characterization and pharmacokinetic properties of antibodies with N-linked Mannose-5 glycans. mAbs 2012; 4:475-87; PMID:22699308; http://dx.doi.org/10.4161/mabs.20737
   PubMed Web of Science ®Google Scholar
• Kumpel B, Rademacher T, Rook G, Williams P, Wilson I. Galactosylation of human IgG monoclonal anti-D produced by EBV-transformed B-lymphoblastoid cell lines is depedent on culture media and affects Fc receptor-mediated functional activity. Hum Antibodies Hybridomas 1994; 5:143-51; PMID:7756579
   PubMedGoogle Scholar
• Hodoniczky J, Zheng YZ, James D. Control of recombinant monoclonal antibody effector functions by Fc N-glycan remodeling in vitro. Biotechnol Prog 2005; 21:1644-52; PMID:16321047; http://dx.doi.org/10.1021/bp050228w
   PubMed Web of Science ®Google Scholar
• Wright A, Morrison S. Effect of altered CH2-associated carbohydrate structure on the functional properties and in vivo fate of chimeric mouse-human immunoglobulin G1. J Exp Med 1994; 180:1087-96; PMID:8064227; http://dx.doi.org/10.1084/jem.180.3.1087
   PubMed Web of Science ®Google Scholar
• Anthony R, Nimmerjahn F, Ashline D, Renhold V, Paulson J, Ravetch J. A recombinant IgG Fc that recapitulates teh anti-inflammitory activity of IVIG. Science 2008; 320:373-6; PMID:18420934; http://dx.doi.org/10.1126/science.1154315
   PubMed Web of Science ®Google Scholar
• Houde D, Peng Y, Berkowitz S, Engen J. Post-translational modifications differentially effect IgG1 conformation and receptor binding. Mol Cell Proteomics 2010; 9:1716-28; PMID:20103567; http://dx.doi.org/10.1074/mcp.M900540-MCP200
   PubMed Web of Science ®Google Scholar
• Malaise M, Franchimont P, Bouillene C, Houssier C, Mahieu P. Increased concanavalin A-binding capacity of immunoglobulin G purified from sera of patients with rheumatoid arthritis. Clin Exp Immunol 1987; 68:543-51
   PubMed Web of Science ®Google Scholar
• Kaneko Y, Nimmerjahn F, Ravetch J. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 2006; 313:670-3; PMID:16888140; http://dx.doi.org/10.1126/science.1129594
   PubMed Web of Science ®Google Scholar
• Visser J, Feuerstein I, Stangler T, Schmiederer T, Fritsch C. Physicochemical and functional comparability between the proposed biosimilar rituximab GP2013 and originator rituximab. BioDrugs 2013; 27:495-507; PMID:23649935; http://dx.doi.org/10.1007/s40259-013-0036-3
   PubMed Web of Science ®Google Scholar
• Rathore A, Winkle H. Quality by design for biopharmaceuticals. Nat Biotechnol 2009; 27:26-34; PMID:19131992; http://dx.doi.org/10.1038/nbt0109-26
   PubMed Web of Science ®Google Scholar
• Goetze A, Liu Y, Zhang Z, Shah B, Lee E, Bondarenko P, Flynn G. High-mannose glycans on the Fc region of therapeutic IgG antibodies increase serum clearance in humans. Glycobiology 2011; 21:949-69; PMID:21421994; http://dx.doi.org/10.1093/glycob/cwr027
   PubMed Web of Science ®Google Scholar
• Chung S, Quarmby V, Gao X, Ying Y, Lin L, Reed C, Fong C, Lau W, Qui Z, Shen A, et al. Quantitative evaluation of fucose reducing effects in a humanized antibody on FcGamma receptor biniding and antibody-dependent cell-mediated cytotoxicity activities. mAbs 2012; 4:326-40; PMID:22531441; http://dx.doi.org/10.4161/mabs.19941
   PubMed Web of Science ®Google Scholar